Costs and consequences of botulinum toxin type A use. Management of children with cerebral palsy in Germany.
This study was a retrospective survey of the management of a cohort of children with cerebral palsy at Seepark Hospital, Germany, who did (cases; n=107) and did not (controls; n=107) receive botulinum toxin injections. Data on healthcare resource use and clinical outcomes over 12 months were collected from the date cases received their first injection and from the date controls were first admitted into hospital. Botulinum toxin use led to an 85% reduction in the number of children requiring surgery. Additionally, controls used significantly more healthcare resources than cases, particularly hospital bed days (69.2+/-34.1 vs. 27.5+/-27.9 days; p <0.0001). The total cost of managing cases and controls was <euro>16,700 and <euro>33,800, respectively. In conclusion, use of botulinum toxin released resources for alternative use during the first year following treatment, without any loss of clinical improvement. However, it is unknown how botulinum toxin affected the need for surgery and associated outcomes in subsequent years.
Ruiz
Francis J
FJ
Catalyst Health Economics Consultants, Northwood, Middlesex, UK.
Guest
Julian F
JF
Lehmann
Almut
A
Davie
Alison M
AM
Güttler
Karen
K
Schlüter
Olaf
O
Dreiss
Götz
G
D000293:Adolescent; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D002547:Cerebral Palsy / Q000188:drug therapy* / Q000191:economics* / Q000601:surgery; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D003365:Costs and Cost Analysis; D005260:Female; D005858:Germany; D006295:Health Resources / Q000706:statistics & numerical data; D006801:Humans; D007902:Length of Stay; D008297:Male; D015999:Multivariate Analysis; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D018579:Patient Selection; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A
Am J Phys Med Rehabil. 2003 Apr;82(4):284-9
12649654
J Pediatr Orthop. 1987 May-Jun;7(3):256-8
3584438
Clin Orthop Relat Res. 1996 Feb;(323):254-60
8625589
J Paediatr Child Health. 1995 Feb;31(1):24-8
7748684
J Paediatr Child Health. 2003 Jan-Feb;39(1):6-14
12542805
Rev Esp Salud Publica. 2000 Sep-Dec;74(5-6):549-59
11217244
Int Orthop. 1992;16(3):291-3
1428346
Clin Orthop Relat Res. 2002 Jan;(394):177-85
11795730
Eur J Neurol. 2001 Nov;8 Suppl 5:145-9
11851743
Gait Posture. 2000 Feb;11(1):67-79
10664488
Arch Phys Med Rehabil. 1977 Apr;58(4):154-7
849129
Med J Aust. 2003 Jan 20;178(2):95-6; author reply 96
12526736
Arch Phys Med Rehabil. 1996 Jul;77(7):717-21
8670002
Int J Clin Pract. 2002 Oct;56(8):564-7
12425363
Acta Neurol Scand. 1995 Jun;91(6):423-32
7572035
Arch Phys Med Rehabil. 2003 Mar;84(3):444-54
12638115
Clin J Pain. 2002 Nov-Dec;18(6 Suppl):S182-90
12569967
J Pediatr Orthop. 1987 May-Jun;7(3):253-5
3584437
Curr Opin Pediatr. 1997 Feb;9(1):81-8
9088760
Eur J Neurol. 2001 Nov;8 Suppl 5:1-20
11851730
Dev Med Child Neurol. 2002 Dec;44(12):820-7
12455858
Clin Orthop Relat Res. 1966 May-Jun;46:7-22
5950310
Arch Dis Child Fetal Neonatal Ed. 1998 Jul;79(1):F21-5
9797620
J Pediatr Orthop. 1992 May-Jun;12(3):329-36
1572996
Phys Ther. 1988 Dec;68(12):1903-12
3057525
J Child Neurol. 1996 Mar;11(2):77-83
8881981
Int Orthop. 1993;17(3):162-5
8340171
Eur J Neurol. 2001 Nov;8 Suppl 5:183-93
11851747
W V Med J. 1994 May;90(5):190-2
8053168
Pediatrics. 2001 Nov;108(5):1062-71
11694682
Eur J Neurol. 2001 Nov;8 Suppl 5:194-202
11851748
J Child Neurol. 1996 Mar;11(2):75-76
8881980
Brain Dev. 1994 Nov-Dec;16(6):423-31
7694988
Neurology. 1994 Nov;44(11 Suppl 9):S60-8; discussion S68-9
7970013
Proc R Soc Med. 1970 Sep;63(9):937-8
5477077